

TALKING ABOUT NALOXONE

WB4518R

PROGRAM DESCRIPTION: This enduring activity is designed improve patient outcomes by increasing naloxone prescribing and communication practices surrounding naloxone.

OBJECTIVES:

At the conclusion of the training, the participant should be able to:

1. List risk factors for opioid-related harms.
2. Select strategies for starting a conversation with patients about naloxone and educating them about the risk of overdose and the role of naloxone in preventing overdoses.
3. Identify how interprofessional care coordination to support offering of naloxone can reduce the risk of opioid overdose.
4. Describe how to communicate about naloxone in a caring, compassionate, and non-stigmatizing manner.

FACULTY/ CREDENTIALS:

Christina A. Mikosz, MD, MPH
Lead Medical Officer, Division of Overdose
Prevention, National Center for Injury
Prevention and Control

Molly Dowling, MPH, CHES
Health Communications Specialist
Division of Overdose Prevention
National Center for Injury Prevention and
Control

ORIGINATION DATE:

May 25, 2022

RENEWAL DATE:

May 25, 2024

EXPIRATION DATE:

May 25, 2026

URL:	https://www.cdc.gov/overdose-prevention/hcp/trainings/talking-about-naloxone.html
HARDWARE/SOFTWARE:	Computer Hardware; Internet Connection; Browser
MATERIALS:	None
TARGET AUDIENCE:	Physicians, Registered Nurses, Other health professionals
PREREQUISITES:	None
FORMAT:	This activity is Web-based .
CONTACT INFORMATION:	Division of Overdose Prevention, National Center for Injury Prevention and Control 800-232-4636,

ACCREDITATION STATEMENTS:



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME: The Centers for Disease Control and Prevention designates this **enduring** activity for a maximum of **1.5** AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention designates this activity for **1.5** nursing contact hours.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer **0.2** CEU's for this program.

DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies during the previous 24 months.

CDC, our planners, and content experts wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.

Instructions for Obtaining Continuing Education (CE)

To receive continuing education (CE) for **WB4518R - Talking about Naloxone**, please visit [CDC TRAIN](#) and search for the course in the Course Catalog using **WB4518R**. Follow the steps below by **05/25/2026**.

1. Register for and complete the course.
2. Pass the post-assessment at 80 %.
3. Complete the evaluation.
4. Visit Your Learning to access your certificates and transcript.

FEES: No fees are charged for CDC's CE activities.